{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:59:32Z","timestamp":1761541172615},"reference-count":24,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ygyno.2013.09.019","type":"journal-article","created":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T02:08:32Z","timestamp":1379642912000},"page":"604-608","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Patterns of relapse in stage I\u2013II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy"],"prefix":"10.1016","volume":"131","author":[{"given":"Neil B.","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana P.","family":"Kiess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa A.","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeem R.","family":"Abu-Rustum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard R.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaled M.","family":"Alektiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.09.019_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2009.06.011","article-title":"Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review","volume":"115","author":"Boruta","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0015","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0020","first-page":"1271","article-title":"Overexpression of HER-2\/neu in uterine serous papillary cancer","volume":"8","author":"Santin","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1006\/gyno.1996.0120","article-title":"p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes","volume":"61","author":"Zheng","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ygyno.2005.08.037","article-title":"Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group","volume":"100","author":"Sutton","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0040","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ygyno.2003.08.027","article-title":"Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy","volume":"91","author":"Huh","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0045","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ygyno.2005.07.104","article-title":"The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC)","volume":"99","author":"Dietrich","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0050","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2008.11.016","article-title":"Stage II uterine papillary serous carcinoma: Carboplatin\/paclitaxel chemotherapy improves recurrence and survival outcomes","volume":"112","author":"Fader","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0055","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ygyno.2007.10.037","article-title":"Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN)","volume":"108","author":"Goldberg","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0060","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2007.01.041","article-title":"Outcomes in surgical stage I uterine papillary serous carcinoma","volume":"105","author":"Havrilesky","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0065","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2005.06.012","article-title":"Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy","volume":"98","author":"Kelly","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0070","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ygyno.2011.09.005","article-title":"The importance of chemotherapy and radiation in uterine papillary serous carcinoma","volume":"123","author":"Viswanathan","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0075","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ygyno.2013.01.025","article-title":"A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium","volume":"129","author":"Jhingran","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0080","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ygyno.2012.07.112","article-title":"Five-year outcomes of adjuvant carboplatin\/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer","volume":"127","author":"Kiess","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0085","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2008.10.006","article-title":"Concurrent carboplatin\/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer","volume":"112","author":"Alektiar","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0360-3016(97)00581-6","article-title":"Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy","volume":"40","author":"Turner","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0095","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0360-3016(90)90094-Z","article-title":"Postoperative vaginal irradiation with high dose rate afterloading technique in endometrial carcinoma stage I","volume":"18","author":"Sorbe","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0100","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/cncr.24247","article-title":"Platinum\/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma","volume":"115","author":"Fader","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0105","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ygyno.2004.05.009","article-title":"High-dose rate brachytherapy for Stage I\/II papillary serous or clear cell endometrial cancer","volume":"94","author":"DuBeshter","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijrobp.2012.03.011","article-title":"The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer","volume":"85","author":"Barney","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2012.12.026","article-title":"Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer","volume":"129","author":"Townamchai","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.09.019_bb0120","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813011931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813011931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T04:16:00Z","timestamp":1563941760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813011931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0090825813011931"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.09.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of relapse in stage I\u2013II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}